Over at Genetic Future, Daniel MacArthur blogs about Complete Genomics and its deal to sequence five genomes for the Broad Institute -- one genome of a well-studied test case, and four from "tumor and matched-pair normals" to study glioblastoma and melanoma. MacArthur spoke with Complete's Geoff Nilsen about accuracy issues.